Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
P/E ratio for Prothena Corporation plc (PRTA)
P/E ratio as of 2023: -13.15
According to Prothena Corporation plc's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -13.15. At the end of 2022 the company had a P/E ratio of -24.40.
P/E ratio history for Prothena Corporation plc from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -13.15 |
| 2022 | -24.40 |
| 2021 | 32.62 |
| 2020 | -4.31 |
| 2019 | -8.13 |
| 2018 | -2.62 |
| 2017 | -9.21 |
| 2016 | -10.55 |
| 2015 | -25.62 |
| 2014 | -71.64 |
| 2013 | -12.04 |
| 2012 | -2.58 |
| 2011 | -4.29 |
| 2010 | -10.20 |